-
-
Overview
-
Dabrafenib is a selective inhibitor of BRAF, a proto-oncogene. It is primarily used for the treatment of late-stage melanoma.
Please contact us at for specific academic pricing.
Background
Dabrafenib is a reversible and potent adenosine triphosphate-competitive inhibitor that selectively inhibits the BRAFV600E kinase.
-
- Properties
-
Overview